Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-7.35%
0%
-7.35%
6 Months
-16.0%
0%
-16.0%
1 Year
14.55%
0%
14.55%
2 Years
-42.18%
0%
-42.18%
3 Years
-73.97%
0%
-73.97%
4 Years
-74.07%
0%
-74.07%
5 Years
-44.25%
0%
-44.25%
Cambridge Cognition Holdings Plc for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
9.01%
EBIT Growth (5y)
2.21%
EBIT to Interest (avg)
-0.97
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0.18
Sales to Capital Employed (avg)
7.25
Tax Ratio
4.45%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
9.00%
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
6.83
EV to EBIT
-10.58
EV to EBITDA
-16.73
EV to Capital Employed
5.01
EV to Sales
1.88
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-47.30%
ROE (Latest)
-71.20%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Bearish (Daily)
KST
Bullish
Mildly Bullish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Annual Results Snapshot (Consolidated) - Dec'22
Dec'22
Dec'21
Change(%)
Net Sales
12.60
10.10
24.75%
Operating Profit (PBDIT) excl Other Income
-0.80
0.70
-214.29%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-0.40
0.40
-200.00%
Operating Profit Margin (Excl OI)
-74.20%
54.20%
-12.84%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2022 is 24.75% vs 50.75% in Dec 2021
Consolidated Net Profit
YoY Growth in year ended Dec 2022 is -200.00% vs 200.00% in Dec 2021
About Cambridge Cognition Holdings Plc 
Cambridge Cognition Holdings Plc
Software Products
Cambridge Cognition Holdings plc and its subsidiaries develop and commercialize computerized neuropsychological tests for sale, principally in the United Kingdom, the United States and Europe. The Company's segments include Pharmaceutical Clinical Trials, Academic Research and Healthcare Technology. The Pharmaceutical Clinical Trials segment includes products and services for use in regulated pharmaceutical clinical trials. The Academic Research segment includes cognitive test products for researchers working in a non-regulated environment, typically in academia. The Healthcare Technology segment includes medical software for use in healthcare delivery settings. The Company is a provider of validated touchscreen cognitive assessments for clinical trials. The Company's product, CANTAB Mobile is a Class II medical device, used to identify patients exhibiting the early signs of Alzheimer's disease. It also offers Cantab Insight for dementia assessment in secondary care.
Company Coordinates 
Company Details
Tunbridge Court, Tunbridge Lane, Bottisham CAMBRIDGE None : CB25 9TU
Registrar Details






